Sorry, you need to enable JavaScript to visit this website.

This site is intended only for healthcare professionals resident in the United Kingdom

Prescribing information can be found at the bottom of the page

Ecalta® (anidulafungin) is an echinocandin indicated for the treatment of invasive candidiasis in adult patients including the following patient populations: non neutropenic patients, neutropenic patients and patients with deep-tissue infections.

Ecalta® (anidulafungin) Mode of Action

Ecalta selectively inhibits 1,3-β-D glucan synthase, an enzyme present in fungal, but not mammalian cells. This results in inhibition of the formation of 1,3-β-D-glucan, an essential component of the fungal cell wall.

 

Watch the MOA Video

Considerations for clinical practice

  • A favourable pharmacokinetic profile compared to other echinocandins1
  • No known drug interactions2,3
  • No dose adjustment required in hepatic or renal impairment2
  • Better efficacy and significantly higher global success rate versus the gold standard fluconazole in the treatment of candidaemia4

Resources & Training

Find related information and test your knowledge with bespoke training modules

Find out more

Stock Hub

Register here to receive real time stock information and email alerts 

Access the Stock Hub

COMT, Catechol-O-methyltransferase

References

  1. Kim R, et al. Expert Opin Pharmacother 2007;8(10):1479–1492.
  2. Ecalta® Summary of Product Characteristics.
  3. Vazquez JA. Clin Ther 2005;27(6):657–673.
  4. Reboli AC, et al. N Engl J Med 2007;356:2472–2482.